Development and validation of a patient‐based disease activity score in rheumatoid arthritis that can be used in clinical trials and routine practice
- 31 January 2008
- journal article
- research article
- Published by Wiley in Arthritis Care & Research
- Vol. 59 (2), 192-199
- https://doi.org/10.1002/art.23342
Abstract
Objective Assessor‐based disease activity measures such as the Disease Activity Score in 28 joints (DAS28), although widely used in rheumatoid arthritis (RA), have high interobserver variability. We developed and validated a patient‐based disease activity score (PDAS) as an alternative assessment. Methods Patients' assessments of swollen or tender joints, visual analog scales for pain and general health, the Health Assessment Questionnaire, and erythrocyte sedimentation rate (ESR) were used to develop the PDAS. In a developmental cohort (204 patients), regression analyses determined the best fit with the DAS28. A validation cohort (322 patients) subsequently evaluated criterion and construct validity against a range of outcome measures, including the Nottingham Health Profile (NHP) and Short Form 36 (SF‐36). Sensitivity to change was assessed in 56 patients after 6 months of treatment with disease‐modifying antirheumatic drugs or biologics. Results In the developmental cohort, the PDAS with ESR (PDAS1) and without ESR (PDAS2) achieved excellent fit with the DAS28 (r = 0.88 and 0.74, respectively). In the validation cohort, the PDAS showed high criterion validity by correlation with the DAS28 (PDAS1: r = 0.89, PDAS2: r = 0.76). Construct validity was demonstrated by high correlations with a range of disease activity measures (r ≥ 0.45), whereas low correlations (r < 0.45) with mental and social components of the SF‐36 and NHP indicated divergent validity. The PDAS and DAS28 had similar sensitivity to change, determined using effect sizes (DAS28 = 1.03, PDAS1 = 1.02, PDAS2 = 0.77) or standardized response means (DAS28 = 0.79, PDAS1 = 0.77, PDAS2 = 0.73). Conclusion The PDAS1 and PDAS2 are valid and sensitive tools to assess disease activity in RA. They appear suitable for clinical decision making, epidemiologic research, and clinical trials.Keywords
This publication has 34 references indexed in Scilit:
- UK consultant rheumatologists' access to biological agents and views on the BSR Biologics RegisterRheumatology, 2006
- Touch-screen computer systems in the rheumatology clinic offer a reliable and user-friendly means of collecting quality-of-life and outcome data from patients with rheumatoid arthritisRheumatology, 2005
- A potential pitfall in the use of the Disease Activity Score (DAS28) as the main response criterion in treatment guidelines for patients with rheumatoid arthritisAnnals Of The Rheumatic Diseases, 2004
- Patient-reported outcomes better discriminate active treatment from placebo in randomized controlled trials in rheumatoid arthritisRheumatology, 2004
- Patient- versus physician-reported outcomes in rheumatoid arthritis patients treated with recombinant interleukin-1 receptor antagonist (anakinra) therapyRheumatology, 2004
- An index of the three core data set patient questionnaire measures distinguishes efficacy of active treatment from that of placebo as effectively as the American College of Rheumatology 20% response criteria (ACR20) or the Disease Activity Score (DAS) in a rheumatoid arthritis clinical trialArthritis & Rheumatism, 2003
- American college of rheumatology preliminary definition of improvement in rheumatoid arthritisArthritis & Rheumatism, 1995
- A self‐administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic researchArthritis & Rheumatism, 1995
- Modified disease activity scores that include twenty-eight-joint counts development and validation in a prospective longitudinal study of patients with rheumatoid arthritisArthritis & Rheumatism, 1995
- The american rheumatism association 1987 revised criteria for the classification of rheumatoid arthritisArthritis & Rheumatism, 1988